Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype

被引:71
作者
Powell, H
Kitteringham, NR
Pirmohamed, M
Smith, DA
Park, BK
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[2] Pfizer Cent Res, Dept Drug Metab, Sandwich, Kent, England
来源
PHARMACOGENETICS | 1998年 / 8卷 / 05期
基金
英国惠康基金;
关键词
CYP2E1; RsaI polymorphism; mRNA; chlorzoxazone; p-nitrophenol;
D O I
10.1097/00008571-199810000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytochrome P4502E1 (CYP2E1) is constitutively expressed in human liver and is responsible for the metabolic bioactivation of a wide variety of xenobiotics, including a number of protoxins and procarcinogens. CYP2E1 expression is regulated at several levels including pre-transcriptional, transcriptional and post-transcriptional levels, and any variation in enzyme concentration and hence activity may represent increased risk of toxicity or carcinogenicity, We have investigated variability in the levels of CYP2E1 mRNA, protein and functional activity in a human liver bank, and attempted to relate these parameters to the RsaI restriction fragment length polymorphism in the 5'-flanking region, Variation in CYP2E1 mRNA (18-fold) was greater than the variation seen in CYP2E1 protein (twofold) and functional activity (fourfold) determined using two probe substrates, chlorzoxazone and p-nitrophenol, Although protein and functional activity showed a significant correlation (r = 0.93 and r = 0.83 for chlorzoxazone and p-nitrophenol, respectively), there was no correlation between ally of these parameters and mRNA levels, Also, the variation in CYP2E1 activity could not be directly accounted for by the RsaI polymorphism in our samples. In conclusion our results are consistent with a complex regulation of CYP2E1 and the fact that it is highly conserved in the human population, The absence of a relationship between the RsaI polymorphism and CYP2E1 activity is consistent with other studies performed in Caucasians, but does not exclude an effect of this polymorphism on inducibility of CYP2E1. Pharmacogenetics 8:411-421 (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:411 / 421
页数:11
相关论文
共 45 条
[1]   Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype [J].
Carriere, V ;
Berthou, F ;
Baird, S ;
Belloc, C ;
Beaune, P ;
deWaziers, I .
PHARMACOGENETICS, 1996, 6 (03) :203-211
[2]  
Gentile DM, 1996, J PHARMACOL EXP THER, V277, P105
[3]   Influence of clinicopathological variables on CYP protein expression in human liver [J].
George, J ;
Byth, K ;
Farrell, GC .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1996, 11 (01) :33-39
[4]  
GEORGE J, 1995, HEPATOLOGY, V21, P120, DOI 10.1016/0270-9139(95)90418-2
[5]   N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity [J].
Gill, HJ ;
Tingle, MD ;
Park, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (06) :531-538
[6]  
GUENGERICH FP, 1991, J PHARMACOL EXP THER, V256, P1189
[7]   EXPRESSION OF XENOBIOTIC-METABOLIZING CYTOCHROME-P450 FORMS IN HUMAN ADULT AND FETAL LIVER [J].
HAKKOLA, J ;
PASANEN, M ;
PURKUNEN, R ;
SAARIKOSKI, S ;
PELKONEN, O ;
MAENPAA, J ;
RANE, A ;
RAUNIO, H .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (01) :59-64
[8]   GENETIC POLYMORPHISMS IN THE 5'-FLANKING REGION CHANGE TRANSCRIPTIONAL REGULATION OF THE HUMAN CYTOCHROME P450IIE1 GENE [J].
HAYASHI, S ;
WATANABE, J ;
KAWAJIRI, K .
JOURNAL OF BIOCHEMISTRY, 1991, 110 (04) :559-565
[9]  
HILDESHEIM A, 1995, CANCER EPIDEM BIOMAR, V4, P607
[10]  
HIROVONEN A, 1993, CARCINOGENESIS, V14, P85